Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim is generally consistent with FDA label indication language in Section 1.1 for LIPITOR cardiovascular risk reduction across the specified adult populations, though it is slightly less specific by implying 'related cardiovascular outcomes' rather than listing the exact outcomes.
Category Scores
Accurate Statements
LIPITOR is indicated to reduce the risk of myocardial infarction and stroke in adult patients without clinically evident coronary heart disease with multiple risk factors, and in patients with type 2 diabetes without clinically evident coronary heart disease with multiple risk factors.
Label Section 1.1 Prevention of Cardiovascular Disease (adult patients without clinically evident coronary heart disease with multiple risk factors; includes reduce risk of myocardial infarction and stroke; and type 2 diabetes without clinically evident coronary heart disease with multiple risk factors; includes reduce risk of myocardial infarction and stroke).
LIPITOR is indicated to reduce cardiovascular events in patients with clinically evident coronary heart disease.
Label Section 1.1 Prevention of Cardiovascular Disease (clinically evident coronary heart disease; includes reduce risk of non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina).
Unsupported Statements
The claim uses the phrase 'related cardiovascular outcomes' without specifying the particular outcomes listed in the label (e.g., revascularization procedures/angina; hospitalization for CHF).
The label enumerates specific outcomes in Section 1.1; the claim is broader/general in wording rather than explicitly matching each outcome.
Contradictions
Important Omissions
For the clinically evident coronary heart disease population, the claim does not explicitly list all outcomes specified in the label (revascularization procedures, hospitalization for CHF, angina).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim concerns FDA-approved indications. While it is slightly less specific about the exact labeled outcomes, it does not introduce a contraindicated use or safety mechanism in the claim provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Outcome wording is generalized ('related cardiovascular outcomes') rather than explicitly listing the specific labeled outcomes.
Suggested Improvement
Replace 'related cardiovascular outcomes' with the exact outcomes enumerated in Section 1.1 for each population (e.g., myocardial infarction, stroke, revascularization procedures/angina; and for clinically evident coronary heart disease include hospitalization for CHF).